The GLP-1 Adherence Crisis
Most GLP-1 patients stop within a year. Here's why adherence — not efficacy — is the defining challenge in metabolic therapy.
GLP-1 drugs work. The adherence crisis is what doesn’t.
Studies consistently show that the majority of patients discontinue GLP-1 therapy within 12 months of starting — often due to cost, side effects, or supply disruption. The clinical evidence for these drugs is strong. The real-world staying power is not.
This post examines the structural barriers to long-term GLP-1 use and what population-level dropout means for cardiovascular and metabolic outcomes.
FAQ
Q: What is the GLP-1 adherence crisis? A: The term describes the widespread pattern of patients stopping GLP-1 therapy within months of starting, despite evidence that long-term use is required to maintain cardiovascular and metabolic benefits.
Q: Why do most patients stop GLP-1 drugs? A: The most common barriers are cost (coverage is limited or time-capped for many patients), gastrointestinal side effects, supply shortages, and the expectation that treatment is temporary rather than chronic.
Q: Does stopping GLP-1 therapy reverse its benefits? A: Yes. Evidence from large cohort studies shows that cardiovascular and metabolic benefits erode within months of stopping, and most patients regain significant weight if no alternative strategy is in place.
Q: Are GLP-1 adherence rates worse than other chronic medications? A: Yes. Discontinuation rates for GLP-1s are substantially higher than for comparable chronic medications like statins or antihypertensives, largely due to cost and tolerability barriers.
Q: Should patients switch GLP-1 drugs instead of stopping entirely? A: In many cases, yes. Tolerability varies between agents — switching from one GLP-1 to another is often preferable to stopping altogether, and should be discussed with a prescriber before discontinuing.
Q: Can health systems do anything to reduce GLP-1 dropout? A: Potentially. Interventions that reduce cost barriers, improve side-effect management, and set realistic long-term expectations at the point of prescribing have all been proposed as ways to improve retention.
Q: Does insurance coverage affect how long patients stay on GLP-1s? A: Significantly. Patients with continuous coverage are far more likely to remain on therapy. Coverage gaps — common with GLP-1s for weight management — are one of the strongest predictors of early discontinuation.